From the blog

A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)

Published: April 22, 2022

Primary Outcome Measures

  1. Incidence of Adverse Events (AEs) [ Time Frame: Up to 6 Months ]
  2. Time to onset of serious adverse events (SAEs) [ Time Frame: Up to 6 Months ]
  3. Time to onset of AEs [ Time Frame: Up to 6 Months ]
  4. Time to resolution of AEs [ Time Frame: Up to 6 Months ]
  5. Time to resolution of SAEs [ Time Frame: Up to 6 Months ]
  6. Incidence of physician seriousness assessment measured by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade – Non-serious AE [ Time Frame: Up to 6 Months ]
  7. Incidence of physician seriousness assessment measured by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade – SAE [ Time Frame: Up to 6 Months ]
  8. Incidence of AEs leading to interruption of treatment [ Time Frame: Up to 6 Months ]
  9. Incidence of SAEs leading to interruption of treatment [ Time Frame: Up to 6 Months ]
  10. Incidence of AEs leading to treatment discontinuation [ Time Frame: Up to 6 Months ]
  11. Incidence of SAEs leading to treatment discontinuation [ Time Frame: Up to 6 Months ]
  12. Outcome of reported AEs [ Time Frame: Up to 6 Months ]
  13. Outcome of reported SAEs [ Time Frame: Up to 6 Months ]
  14. Number of participants with Yervoy and Opdivo treatment related adverse events as assessed by physician causality [ Time Frame: Up to 6 Months ]
  15. Number of participants with Yervoy and Opdivo treatment unrelated adverse events as assessed by physician causality [ Time Frame: Up to 6 Months ]

Inclusion Criteria

  • Initiated treatment with Yervoy and Opdivo in combination for the first time in accordance with the Japanese package insert

Exclusion Criteria

  • Received combination therapy with Yervoy and Opdivo for indications other than Malignant Pleural Mesothelioma (MPM).
  • Received the Yervoy and Opdivo combination for MPM, but for an indication that is outside of the Japanese package insert.
Contact Us
CONTACT INFORMATION
DIAGNOSIS
Have you received a diagnosis? *
reCAPTCHA